News
Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...
Ten Mayo men were part of the AbbVie squad that captured the All-Ireland Intermediate Interfirms title, defeating Boston ...
Zacks Investment Research on MSN18h
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?The first-quarter 2025 earnings season for the Medical sector is about to pick up pace this week. The sector mainly comprises ...
Zacks Investment Research on MSN18h
Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. That is because the May 16, 2025 $125.00 Call had some of the highest implied ...
Scotiabank analyst Louise Chen initiated coverage with a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...
Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie (ABBV) with an Overweight rating and $210 price target AbbVie offers a ...
AbbVie’s stock has analysts in a polite disagreement—some say “buy,” others say “meh,” but no one’s yelling “sell.” The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback